Relevance of Ultrasound Screening for Foetal Macrosomia
USmacro
1 other identifier
observational
3,000
1 country
1
Brief Summary
Management of fetal macrosomia is based on a suspicion of macrosomia (no certainty before birth). This management is an artificial induction of labour for an earlier delivery and therefore a lower fetal weight gain. Several studies have already shown that ultrasound performed during the third trimester of pregnancy was not a perfect tool for this screening.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started Jun 2020
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
June 1, 2020
CompletedFirst Submitted
Initial submission to the registry
June 17, 2020
CompletedFirst Posted
Study publicly available on registry
June 23, 2020
CompletedPrimary Completion
Last participant's last visit for primary outcome
September 1, 2021
CompletedStudy Completion
Last participant's last visit for all outcomes
December 1, 2021
CompletedJune 23, 2020
June 1, 2020
1.3 years
June 17, 2020
June 22, 2020
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Foetal macrosomia
estimated weight above the 90th percentile of the curves of the French College of Fetal Ultrasound during the third trimester ultrasound
Baseline
Study Arms (3)
no macrosomy
pregnant women whose child is not macrosomal
screened macrosomy
pregnant women whose child is macrosomal and have been screened g using ultrasound during the third trimester of pregnancy
no screened macrosomy
pregnant women whose child is macrosomal and havenot been screened g using ultrasound during the third trimester of pregnancy
Interventions
Eligibility Criteria
Pregnant women
You may qualify if:
- Women pregnant Women followed in the gynaecology and obstetrics department of the CHU of Reims, the CHG of Charleville Mézières or the CHG of Chalons en Champagne.
- Women for which the delivery is planned in the gynaecology and obstetrics department of the Reims University Hospital, the Charleville Mézières General Hospital or the Chalons en Champagne General Hospital.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- CHU de Reimslead
Study Sites (1)
Damien JOLLY
Reims, France
MeSH Terms
Conditions
Interventions
Condition Hierarchy (Ancestors)
Intervention Hierarchy (Ancestors)
Central Study Contacts
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- PROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
June 17, 2020
First Posted
June 23, 2020
Study Start
June 1, 2020
Primary Completion
September 1, 2021
Study Completion
December 1, 2021
Last Updated
June 23, 2020
Record last verified: 2020-06